Jamaica
Tuberculosis profile
| High HIV burden |
Population  2012 2.8 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.22 (0.18–0.26)
Mortality (HIV+TB only) 0.013 (0.01–0.016) 0.46 (0.37–0.57)
Prevalence  (includes HIV+TB) 0.26 (0.13–0.44) 9.5 (4.7–16)
Incidence  (includes HIV+TB) 0.18 (0.15–0.22) 6.6 (5.4–7.8)
Incidence (HIV+TB only) 0.04 (0.033–0.048) 1.5 (1.2–1.7)
Case detection, all forms (%) 50 (42–61)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 46 (52) Relapse 3 (50)
Smear-negative 16 (18) Treatment after failure 0 (0)
Smear-unknown / not done 17 (19) Treatment after default 3 (50)
Extrapulmonary 9 (10) Other 0 (0)
Other 0 (0)      
Total new 88   Total retreatment 6  
           
Other (history unknown) 0        
Total new and relapse 91   Total cases notified 94  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.5 1.2 2.0
Age < 15 2 9 0
Laboratories 2012
Smear (per 100 000 population) 0.1
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 47   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 40  
Retreatment 25  
TB/HIV 2012 Number (%)
TB patients with known HIV status 65 (69)
HIV-positive TB patients 13 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.4–3.1) 14 (4.6–23)
MDR-TB cases among notified pulmonary
TB cases
2 (1–2) 1 (0–1)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 16 (28%) 0 (0%) 16
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) <1
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data